How does Vidalista 2.5 affect the nitric oxide-cGMP pathway?

Homepage Forums Products How does Vidalista 2.5 affect the nitric oxide-cGMP pathway?

Viewing 1 post (of 1 total)
  • Author
    Posts
  • #56917
    Clifford Foster
    Participant

    Vidalista 2.5 contains Tadalafil, which is a phosphodiesterase type 5 (PDE5) inhibitor. It works by inhibiting the enzyme PDE5, which is responsible for breaking down cyclic guanosine monophosphate (cGMP) in the smooth muscle cells of the penis. The nitric oxide (NO)-cGMP pathway plays a crucial role in erectile function. When a man is sexually stimulated, nitric oxide is released in the penis, which activates an enzyme called guanylate cyclase. Guanylate cyclase then converts guanosine triphosphate (GTP) into cyclic guanosine monophosphate (cGMP). cGMP causes the smooth muscles in the penis to relax, allowing blood to flow into the erectile tissues and produce an erection. However, PDE5 naturally breaks down cGMP, limiting its action and causing the smooth muscle to contract again, leading to the end of the erection. By inhibiting PDE5, medications like Vidalista 2.5mg prevent the breakdown of cGMP, allowing it to accumulate and prolonging its effects on smooth muscle relaxation and blood flow in the penis. This results in improved erectile function and the ability to achieve and maintain an erection during sexual stimulation.

Viewing 1 post (of 1 total)
  • You must be logged in to reply to this topic.